Corrigendum: Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice (American Journal of Ophthalmology (2018) 191 (83–91), (S0002939418301703) (10.1016/j.ajo.2018.04.010));Vision Outcomes Following Anti–Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice

American Journal of Ophthalmology

Volumn 191, Issue , 2018, Pages 83-91

  Holekamp, Nancy M ^a   Campbell, Joanna ^b   Almony, Arghavan ^c   Ingraham, Herbert ^d   Marks, Steven ^d   Chandwani, Hitesh ^b   Cole, Ashley L ^b   Kiss, Szilárd ^e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

^c Carolina Eye Associates   (United States)

^d GEISINGER HEALTH SYSTEM   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ADULT; ARTICLE; BEST CORRECTED VISUAL ACUITY; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; FEMALE; HUMAN; INTERVENTION STUDY; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VISION; VISUAL EVOKED POTENTIAL; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; TIME FACTOR; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85046764254     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2018.08.023     Document Type: Erratum

References (31)

1. Centers for Disease Control and Prevention, National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Available at: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. (Accessed 10 July 2017)
2. Liew, G., Michaelides, M., Bunce, C., A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open, 4(2), 2014, e004015.
3. Buch, H., Vinding, T., La Cour, M., Appleyard, M., Jensen, G.B., Nielsen, N.V., Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study. Ophthalmology 111:1 (2004), 53–61.
4. Antonetti, D.A., Klein, R., Gardner, T.W., Diabetic retinopathy. N Engl J Med 366:13 (2012), 1227–1239.
5. Yau, J.W., Rogers, S.L., Kawasaki, R., et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:3 (2012), 556–564.
6. National Eye Institute, Diabetic retinopathy. Available at: http://www.nei.nih.gov/eyedata/diabetic.asp. (Accessed 10 July 2017)
7. Varma, R., Bressler, N.M., Doan, Q.V., et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol 132:11 (2014), 1334–1340.
8. Antcliff, R.J., Marshall, J., The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:4 (1999), 223–232.
9. Zhang, X., Zeng, H., Bao, S., Wang, N., Gillies, M.C., Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci, 4, 2014, 27.
10. Ehrlich, R., Harris, A., Ciulla, T.A., Kheradiya, N., Winston, D.M., Wirostko, B., Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol 88:3 (2010), 279–291.
11. Ferrara, N., Gerber, H.P., LeCouter, J., The biology of VEGF and its receptors. Nature Med 9:6 (2003), 669–676.
12. Qaum, T., Xu, Q., Joussen, A.M., et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:10 (2001), 2408–2413.
13. Ford, J.A., Lois, N., Royle, P., Clar, C., Shyangdan, D., Waugh, N., Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open, 3(3), 2013, e002269.
14. Bandello, F., Cunha-Vaz, J., Chong, N.V., et al. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye (Lond) 26:4 (2012), 485–493.
15. Massin, P., Bandello, F., Garweg, J.G., et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33:11 (2010), 2399–2405.
16. Mitchell, P., Bandello, F., Schmidt-Erfurth, U., et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118:4 (2011), 615–625.
17. Nguyen, Q.D., Brown, D.M., Marcus, D.M., et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:4 (2012), 789–801.
18. Elman, M.J., Aiello, L.P., Beck, R.W., et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117:6 (2010), 1064–1077 e1035.
19. Elman, M.J., Bressler, N.M., Qin, H., et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118:4 (2011), 609–614.
20. Michaelides, M., Kaines, A., Hamilton, R.D., et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 117:6 (2010), 1078–1086 e1072.
21. Korobelnik, J.F., Do, D.V., Schmidt-Erfurth, U., et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121:11 (2014), 2247–2254.
22. Ishibashi, T., Li, X., Koh, A., et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology 122:7 (2015), 1402–1415.
23. Kiss, S., Liu, Y., Brown, J., et al. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol 8 (2014), 1611–1621.
24. VanderBeek, B.L., Shah, N., Parikh, P.C., Ma, L., Trends in the care of diabetic macular edema: analysis of a national cohort. PloS One, 11(2), 2016, e0149450.
25. Gregori, N.Z., Feuer, W., Rosenfeld, P.J., Novel method for analyzing Snellen visual acuity measurements. Retina 30:7 (2010), 1046–1050.
26. Rezaei, K.A., Stone, T.W., 2014 Global trends in retina survey. 2014, American Society of Retina Specialists, Chicago, IL Available at: www.asrs.org/content/documents/2014_global_trends_comprehensivepostmtg. (Accessed 10 July 2017)
27. The Diabetic Retinopathy Clinical Research Network, Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:13 (2015), 1193–1203.
28. Wallick, C.J., Hansen, R.N., Campbell, J., Kiss, S., Kowalski, J.W., Sullivan, S.D., Comorbidity and health care resource use among commercially insured non-elderly patients with diabetic macular edema. OSLI Retina 46:7 (2015), 744–751.
29. Dong, L.M., Marsh, M.J., Hawkins, B.S., Measurement and analysis of visual acuity in multicenter randomized clinical trials in the United States: findings from a survey. Ophthalmic Epidemiol 10:3 (2003), 149–165.
30. Fong, D.S., Luong, T.Q., Contreras, R., et al. Treatment patterns and two-year vision outcomes with bevacizumab in diabetic macular edema: an analysis from a large U.S. integrated health care system. Retina, 2017, 10.1097/IAE.0000000000001790.
31. Bearelly, S., Mruthyunjaya, P., Tzeng, J.P., et al. Identification of patients with diabetic macular edema from claims data: a validation study. Arch Ophthalmol 126:7 (2008), 986–989.